Acquired alkylating drug resistance of a human ovarian carcinoma cell line is unaffected by altered levels of pro- and anti-apoptotic proteins

Gargi Roy, Julie K. Horton, Rabindra Roy, Timothy Denning, Sankar Mitra, Istvan Boldogh

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

In a systematic study to elucidate the involvement of pro-and anti-apoptotic proteins in alkylating drug resistance of tumor cells, we utilized the A2780(100) line, that was selected by repeated exposure of A2780 cell line (human ovarian carcinoma line) to chlorambucil (CBL). A2780(100) was 5-10-fold more resistant to nitrogen mustards (IC50 of 50-60 μM) and other DNA crosslinking agents, e.g., cisplatin, and also to DNA topoisomerase inhibitor etoposide (ETO) than A2780. CBL (125 μM) induced extensive apoptosis in A2780 associated with mitochondrial damage but not in A2780(100). No significant differences were observed between A2780 and A2780(100) cells in the basal levels, or the enhanced levels in some cases after CBL treatment, of DNA repair proteins involved in repair of alkyl base adducts or in repair of DNA crosslinks or double strand break repair. However, the basal levels of anti-apoptotic proteins Bcl-x(L) and Mcl-1 were 4-8-fold higher in A2780(100) than in A2780 neither of which expressed Bcl-2. In contrast, the levels of pro-apoptotic Bax and Bak were 3-5-fold higher in the CBL-treated A2780 but not in A2780(100). ETO (5 μM) induced apoptosis in A2780 without altering the levels of Bax and Bak in these cells. At the same time, neither overexpression of Bcl-x(L), in A2780, nor its antisense expression in A2780(100), and nor overexpression of Bax in A2780(100), significantly affected drug sensitivity of either line. Our results suggest that a change in an early step in DNA damage processing which affects intracellular signaling, such as enhanced DNA double-strand break repair, could be the primary cause for development of resistance in A2780(100) cells to drugs which induce DNA crosslinks or double strand-breaks.

Original languageEnglish (US)
Pages (from-to)141-150
Number of pages10
JournalOncogene
Volume19
Issue number1
StatePublished - Jan 6 2000

Fingerprint

Chlorambucil
Apoptosis Regulatory Proteins
Drug Resistance
Carcinoma
Cell Line
Etoposide
DNA Repair
Topoisomerase Inhibitors
Apoptosis
Mechlorethamine
Double-Stranded DNA Breaks
DNA
Pharmaceutical Preparations
Cisplatin
Inhibitory Concentration 50
DNA Damage
Neoplasms
Proteins

Keywords

  • Alkylating drugs
  • Apoptosis
  • Bcl-2 family
  • Drug resistance
  • Pro- and anti-apoptotic proteins

ASJC Scopus subject areas

  • Molecular Biology
  • Cancer Research
  • Genetics

Cite this

Acquired alkylating drug resistance of a human ovarian carcinoma cell line is unaffected by altered levels of pro- and anti-apoptotic proteins. / Roy, Gargi; Horton, Julie K.; Roy, Rabindra; Denning, Timothy; Mitra, Sankar; Boldogh, Istvan.

In: Oncogene, Vol. 19, No. 1, 06.01.2000, p. 141-150.

Research output: Contribution to journalArticle

Roy, Gargi ; Horton, Julie K. ; Roy, Rabindra ; Denning, Timothy ; Mitra, Sankar ; Boldogh, Istvan. / Acquired alkylating drug resistance of a human ovarian carcinoma cell line is unaffected by altered levels of pro- and anti-apoptotic proteins. In: Oncogene. 2000 ; Vol. 19, No. 1. pp. 141-150.
@article{d09705695d8649c6afb832dc2329ca5b,
title = "Acquired alkylating drug resistance of a human ovarian carcinoma cell line is unaffected by altered levels of pro- and anti-apoptotic proteins",
abstract = "In a systematic study to elucidate the involvement of pro-and anti-apoptotic proteins in alkylating drug resistance of tumor cells, we utilized the A2780(100) line, that was selected by repeated exposure of A2780 cell line (human ovarian carcinoma line) to chlorambucil (CBL). A2780(100) was 5-10-fold more resistant to nitrogen mustards (IC50 of 50-60 μM) and other DNA crosslinking agents, e.g., cisplatin, and also to DNA topoisomerase inhibitor etoposide (ETO) than A2780. CBL (125 μM) induced extensive apoptosis in A2780 associated with mitochondrial damage but not in A2780(100). No significant differences were observed between A2780 and A2780(100) cells in the basal levels, or the enhanced levels in some cases after CBL treatment, of DNA repair proteins involved in repair of alkyl base adducts or in repair of DNA crosslinks or double strand break repair. However, the basal levels of anti-apoptotic proteins Bcl-x(L) and Mcl-1 were 4-8-fold higher in A2780(100) than in A2780 neither of which expressed Bcl-2. In contrast, the levels of pro-apoptotic Bax and Bak were 3-5-fold higher in the CBL-treated A2780 but not in A2780(100). ETO (5 μM) induced apoptosis in A2780 without altering the levels of Bax and Bak in these cells. At the same time, neither overexpression of Bcl-x(L), in A2780, nor its antisense expression in A2780(100), and nor overexpression of Bax in A2780(100), significantly affected drug sensitivity of either line. Our results suggest that a change in an early step in DNA damage processing which affects intracellular signaling, such as enhanced DNA double-strand break repair, could be the primary cause for development of resistance in A2780(100) cells to drugs which induce DNA crosslinks or double strand-breaks.",
keywords = "Alkylating drugs, Apoptosis, Bcl-2 family, Drug resistance, Pro- and anti-apoptotic proteins",
author = "Gargi Roy and Horton, {Julie K.} and Rabindra Roy and Timothy Denning and Sankar Mitra and Istvan Boldogh",
year = "2000",
month = "1",
day = "6",
language = "English (US)",
volume = "19",
pages = "141--150",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Acquired alkylating drug resistance of a human ovarian carcinoma cell line is unaffected by altered levels of pro- and anti-apoptotic proteins

AU - Roy, Gargi

AU - Horton, Julie K.

AU - Roy, Rabindra

AU - Denning, Timothy

AU - Mitra, Sankar

AU - Boldogh, Istvan

PY - 2000/1/6

Y1 - 2000/1/6

N2 - In a systematic study to elucidate the involvement of pro-and anti-apoptotic proteins in alkylating drug resistance of tumor cells, we utilized the A2780(100) line, that was selected by repeated exposure of A2780 cell line (human ovarian carcinoma line) to chlorambucil (CBL). A2780(100) was 5-10-fold more resistant to nitrogen mustards (IC50 of 50-60 μM) and other DNA crosslinking agents, e.g., cisplatin, and also to DNA topoisomerase inhibitor etoposide (ETO) than A2780. CBL (125 μM) induced extensive apoptosis in A2780 associated with mitochondrial damage but not in A2780(100). No significant differences were observed between A2780 and A2780(100) cells in the basal levels, or the enhanced levels in some cases after CBL treatment, of DNA repair proteins involved in repair of alkyl base adducts or in repair of DNA crosslinks or double strand break repair. However, the basal levels of anti-apoptotic proteins Bcl-x(L) and Mcl-1 were 4-8-fold higher in A2780(100) than in A2780 neither of which expressed Bcl-2. In contrast, the levels of pro-apoptotic Bax and Bak were 3-5-fold higher in the CBL-treated A2780 but not in A2780(100). ETO (5 μM) induced apoptosis in A2780 without altering the levels of Bax and Bak in these cells. At the same time, neither overexpression of Bcl-x(L), in A2780, nor its antisense expression in A2780(100), and nor overexpression of Bax in A2780(100), significantly affected drug sensitivity of either line. Our results suggest that a change in an early step in DNA damage processing which affects intracellular signaling, such as enhanced DNA double-strand break repair, could be the primary cause for development of resistance in A2780(100) cells to drugs which induce DNA crosslinks or double strand-breaks.

AB - In a systematic study to elucidate the involvement of pro-and anti-apoptotic proteins in alkylating drug resistance of tumor cells, we utilized the A2780(100) line, that was selected by repeated exposure of A2780 cell line (human ovarian carcinoma line) to chlorambucil (CBL). A2780(100) was 5-10-fold more resistant to nitrogen mustards (IC50 of 50-60 μM) and other DNA crosslinking agents, e.g., cisplatin, and also to DNA topoisomerase inhibitor etoposide (ETO) than A2780. CBL (125 μM) induced extensive apoptosis in A2780 associated with mitochondrial damage but not in A2780(100). No significant differences were observed between A2780 and A2780(100) cells in the basal levels, or the enhanced levels in some cases after CBL treatment, of DNA repair proteins involved in repair of alkyl base adducts or in repair of DNA crosslinks or double strand break repair. However, the basal levels of anti-apoptotic proteins Bcl-x(L) and Mcl-1 were 4-8-fold higher in A2780(100) than in A2780 neither of which expressed Bcl-2. In contrast, the levels of pro-apoptotic Bax and Bak were 3-5-fold higher in the CBL-treated A2780 but not in A2780(100). ETO (5 μM) induced apoptosis in A2780 without altering the levels of Bax and Bak in these cells. At the same time, neither overexpression of Bcl-x(L), in A2780, nor its antisense expression in A2780(100), and nor overexpression of Bax in A2780(100), significantly affected drug sensitivity of either line. Our results suggest that a change in an early step in DNA damage processing which affects intracellular signaling, such as enhanced DNA double-strand break repair, could be the primary cause for development of resistance in A2780(100) cells to drugs which induce DNA crosslinks or double strand-breaks.

KW - Alkylating drugs

KW - Apoptosis

KW - Bcl-2 family

KW - Drug resistance

KW - Pro- and anti-apoptotic proteins

UR - http://www.scopus.com/inward/record.url?scp=0034610802&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034610802&partnerID=8YFLogxK

M3 - Article

VL - 19

SP - 141

EP - 150

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 1

ER -